LA |
locally advanced |
BC |
breast cancer |
HR+ |
hormone receptor positive |
pCR |
pathological complete response |
NCT |
neoadjuvant chemotherapy |
NET |
neoadjuvant endocrine therapy |
ER |
estrogen receptors |
PgR |
progesterone receptors |
HER2- |
hormone epidermal growth factor 2 negative |
TN |
triple negative |
BCS |
breast conservative surgery |
ObR |
objective response |
PEPI |
preoperative endocrine prognostic index |
DBs |
databases |
CENTRAL |
Cochrane Central Register of Controlled Trials |
MeSH |
Medical Subject Headings |
ASCO |
American Society of Clinical Oncology |
AACR |
American Association of Cancer Research |
OS |
overall survival |
OR |
odds ratio |
CI |
confidence interval |
DFS |
disease free survival |
ORR |
overall response rate |
EC |
epirubicin-cyclophosphamide |
RFS |
relapse free survival |
pATR |
phosphorylated ataxia-teleangectasia and Rad3-related protein |
ATM |
phosphorylated ataxia-telangiectasia mutated |
γ-H2AX |
phosphorylated H2A Histone Family Member X |
CCCA |
complete cell cycle arrest |
RCB |
residual cancer burden |
eBC |
early breast cancer |
PI3K |
phosphatidylinositol-4,5-bisphosphate 3-kinase |
PIK3CA |
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
AKT1 |
RAC-alpha serine/threonine-protein kinase |
PTEN |
Phosphatase and tensin homolog |
FGFR1 |
fibroblast grow factor receptor 1 |
TILs |
Tumor-infiltrating lymphocytes |
PD-L1 |
Programmed death-ligand 1 |
PD-1 |
Programmed death-1 |
POAI |
peri-operative aromatase inhibitor |
TTR |
time to recurrence |
WoTs |
window of opportunity trials |
CDK4/6 |
cyclin-dependent kinase 4 and 6 |